Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.76 |
| ▸ | EGFR | P00533 | 9/20 | 0.76 |
| ▸ | WEE1 | P30291 | 8/20 | 0.76 |
| ▸ | SRC | P12931 | 8/20 | 0.76 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.76 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.76 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.76 |
| ▸ | ABL1 | P00519 | 5/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.64 |
| ▸ | KIT | P10721 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249826 | 0.92 | FGFR1 (0.76) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2252578 | 0.92 | FGFR1 (0.76) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL14222154 | 0.91 | FGFR1 (0.66) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2248039 | 0.91 | FGFR1 (0.66) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2247623 | 0.91 | WEE1 (0.61) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2242561 | 0.90 | FGFR1 (0.81) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2246710 | 0.90 | FGFR1 (0.77) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2246051 | 0.88 | SRC (0.67) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2248640 | 0.88 | FGFR1 (0.68) | FGFR1EGFRWEE1SRCFGFR2 | |
| SCHEMBL2249998 | 0.88 | FGFR1 (0.62) | FGFR1EGFRWEE1SRCFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | claimed |
| EP-2084159-A1 | PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC Biotech Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | claimed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2084159-A1 | PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC Biotech Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008150260-A1 | 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS | GPC BIOTECH, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150260-A1 | 8-OXY-2-AMINOPYRIDO (2, 3-D) PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND ANTICANCER AGENTS | GPC BIOTECH, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | FGFR1 745/4885EGFR 816/4885WEE1 331/4885 |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | DCK, PDXK, TK1 | FGFR1 818/4885EGFR 887/4885WEE1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.